223 related articles for article (PubMed ID: 15120043)
1. Modelling approaches for angiogenesis.
Taraboletti G; Giavazzi R
Eur J Cancer; 2004 Apr; 40(6):881-9. PubMed ID: 15120043
[TBL] [Abstract][Full Text] [Related]
2. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy.
D'Onofrio A; Gandolfi A
Math Med Biol; 2009 Mar; 26(1):63-95. PubMed ID: 19033598
[TBL] [Abstract][Full Text] [Related]
3. In-vitro and in-vivo assays for angiogenesis-modulating drug discovery and development.
Phung MW; Dass CR
J Pharm Pharmacol; 2006 Feb; 58(2):153-60. PubMed ID: 16451742
[TBL] [Abstract][Full Text] [Related]
4. Mammalian tumor xenografts induce neovascularization in zebrafish embryos.
Nicoli S; Ribatti D; Cotelli F; Presta M
Cancer Res; 2007 Apr; 67(7):2927-31. PubMed ID: 17409396
[TBL] [Abstract][Full Text] [Related]
5. Selective targeting of the tumour vasculature.
Chan LS; Daruwalla J; Christophi C
ANZ J Surg; 2008 Nov; 78(11):955-67. PubMed ID: 18959693
[TBL] [Abstract][Full Text] [Related]
6. Microtubule-targeting agents in angiogenesis: where do we stand?
Pasquier E; Honoré S; Braguer D
Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139
[TBL] [Abstract][Full Text] [Related]
7. The angiogenic process as a therapeutic target in cancer.
Bridges EM; Harris AL
Biochem Pharmacol; 2011 May; 81(10):1183-91. PubMed ID: 21382350
[TBL] [Abstract][Full Text] [Related]
8. Are tumours angiogenesis-dependent?
Verheul HM; Voest EE; Schlingemann RO
J Pathol; 2004 Jan; 202(1):5-13. PubMed ID: 14694516
[TBL] [Abstract][Full Text] [Related]
9. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of angiogenesis and cancer.
Tonini T; Rossi F; Claudio PP
Oncogene; 2003 Sep; 22(42):6549-56. PubMed ID: 14528279
[TBL] [Abstract][Full Text] [Related]
11. Tumor endothelial cells are targets for selective therapies: in vitro and in vivo models to evaluate antiangiogenic strategies.
Dutour A; Rigaud M
Anticancer Res; 2005; 25(6B):3799-807. PubMed ID: 16309166
[TBL] [Abstract][Full Text] [Related]
12. [Dormant tumors and organs resistant to metastasis after gene transfer: dream and reality of anti-angiogenic gene therapy].
Li H; Dkhissi F; Grenet C; Soria C; Lu H
Therapie; 2001; 56(5):501-10. PubMed ID: 11806286
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of the tumor vasculature.
Tozer GM; Bicknell R
Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis inhibitors in cancer therapy.
Dredge K; Dalgleish AG; Marriott JB
Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
[TBL] [Abstract][Full Text] [Related]
15. Design and development of polymer conjugates as anti-angiogenic agents.
Segal E; Satchi-Fainaro R
Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
Horsman MR; Siemann DW
Cancer Res; 2006 Dec; 66(24):11520-39. PubMed ID: 17178843
[TBL] [Abstract][Full Text] [Related]
17. Vascular damaging agents.
Patterson DM; Rustin GJ
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
[TBL] [Abstract][Full Text] [Related]
18. Mitochondria as targets in angiogenesis inhibition.
Park D; Dilda PJ
Mol Aspects Med; 2010 Feb; 31(1):113-31. PubMed ID: 19995570
[TBL] [Abstract][Full Text] [Related]
19. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999).
d'Onofrio A; Gandolfi A
Math Biosci; 2004 Oct; 191(2):159-84. PubMed ID: 15363652
[TBL] [Abstract][Full Text] [Related]
20. Cancer angiogenesis: targeting the heel of Achilles.
Dass CR; Choong PF
J Drug Target; 2008 Jul; 16(6):449-54. PubMed ID: 18604657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
